NYSE:XON - Intrexon Stock Price, Price Target & More

$18.02 +0.16 (+0.90 %)
(As of 04/25/2018 02:18 PM ET)
Previous Close$17.86
Today's Range$17.46 - $18.23
52-Week Range$10.26 - $26.99
Volume342,767 shs
Average Volume1.77 million shs
Market Capitalization$2.32 billion
P/E Ratio-19.64
Dividend YieldN/A
Beta1.11

About Intrexon (NYSE:XON)

Intrexon logoIntrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Receive XON News and Ratings via Email

Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNYSE:XON
CUSIPN/A
Phone301-556-9900

Debt

Debt-to-Equity Ratio0.01%
Current Ratio1.92%
Quick Ratio1.67%

Price-To-Earnings

Trailing P/E Ratio-19.64
Forward P/E Ratio-19.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$230.98 million
Price / Sales10.07
Cash FlowN/A
Price / CashN/A
Book Value$4.29 per share
Price / Book4.20

Profitability

EPS (Most Recent Fiscal Year)($0.92)
Net Income$-117,010,000.00
Net Margins-50.61%
Return on Equity-16.94%
Return on Assets-10.47%

Miscellaneous

Employees1,006
Outstanding Shares129,070,000

How to Become a New Pot Stock Millionaire

Intrexon (NYSE:XON) Frequently Asked Questions

What is Intrexon's stock symbol?

Intrexon trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON."

How were Intrexon's earnings last quarter?

Intrexon (NYSE:XON) posted its quarterly earnings data on Thursday, March, 1st. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. The biotechnology company earned $77.03 million during the quarter, compared to analyst estimates of $48.16 million. Intrexon had a negative return on equity of 16.94% and a negative net margin of 50.61%. Intrexon's revenue was up 67.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.37) EPS. View Intrexon's Earnings History.

When is Intrexon's next earnings date?

Intrexon is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Intrexon.

What price target have analysts set for XON?

6 analysts have issued 1 year price objectives for Intrexon's stock. Their predictions range from $17.00 to $57.00. On average, they anticipate Intrexon's share price to reach $34.6667 in the next year. View Analyst Ratings for Intrexon.

Who are some of Intrexon's key competitors?

Who are Intrexon's key executives?

Intrexon's management team includes the folowing people:
  • Mr. Randal J. Kirk, Chairman and Chief Exec. Officer (Age 65)
  • Mr. Rick L. Sterling, Chief Financial Officer (Age 54)
  • Mr. Nir Nimrodi, Chief Bus. Officer (Age 49)
  • Dr. Thomas D. Reed Ph.D., Founder and Chief Science Officer (Age 52)
  • Lieutenant General Thomas P. Bostick, Chief Operating Officer

Has Intrexon been receiving favorable news coverage?

Media headlines about XON stock have been trending positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intrexon earned a media sentiment score of 0.44 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 47.82 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Intrexon?

Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intrexon's stock price today?

One share of XON stock can currently be purchased for approximately $18.02.

How big of a company is Intrexon?

Intrexon has a market capitalization of $2.32 billion and generates $230.98 million in revenue each year. The biotechnology company earns $-117,010,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Intrexon employs 1,006 workers across the globe.

How can I contact Intrexon?

Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]


MarketBeat Community Rating for Intrexon (XON)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intrexon (NYSE:XON) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Intrexon in the last 12 months. Their average twelve-month price target is $34.6667, suggesting that the stock has a possible upside of 92.38%. The high price target for XON is $57.00 and the low price target for XON is $17.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.832.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $34.6667$34.6667$38.50$43.20
Price Target Upside: 92.38% upside128.07% upside225.99% upside111.87% upside

Intrexon (NYSE:XON) Consensus Price Target History

Price Target History for Intrexon (NYSE:XON)

Intrexon (NYSE:XON) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2018JPMorgan ChaseReiterated RatingNeutral -> Neutral$22.00 -> $18.00HighView Rating Details
3/2/2018Bank of AmericaLower Price TargetNeutral -> Neutral$21.00 -> $19.00MediumView Rating Details
3/2/2018Northland SecuritiesReiterated RatingBuy$17.00HighView Rating Details
11/10/2017Stifel NicolausBoost Price TargetBuy$39.00 -> $57.00N/AView Rating Details
10/6/2017Griffin SecuritiesReiterated RatingBuy$55.00N/AView Rating Details
10/5/2017JMP SecuritiesReiterated RatingOutperform$42.00N/AView Rating Details
3/14/2017WunderlichLower Price TargetBuy$50.00 -> $35.00HighView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Intrexon (NYSE:XON) Earnings History and Estimates Chart

Earnings by Quarter for Intrexon (NYSE:XON)

Intrexon (NYSE:XON) Earnings Estimates

2018 EPS Consensus Estimate: ($0.92)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.23)($0.23)($0.23)
Q3 20181($0.24)($0.24)($0.24)
Q4 20181($0.24)($0.24)($0.24)

Intrexon (NYSE XON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.25)N/AView Earnings Details
3/1/2018Q4 2017($0.31)($0.23)$48.16 million$77.03 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.22)($0.20)$55.17 million$46.02 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.21)($0.16)$57.17 million$54.40 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.22)($0.26)$49.08 million$53.70 millionViewN/AView Earnings Details
3/1/2017Q416($0.23)($0.3720)$52.53 million$46.00 millionViewListenView Earnings Details
11/9/2016Q316($0.21)($0.24)$51.70 million$48.99 millionViewListenView Earnings Details
8/9/2016Q216($0.26)($0.42)$53.78 million$52.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.20)($0.55)$46.26 million$43.40 millionViewListenView Earnings Details
2/29/2016Q415($0.18)($0.28)$41.82 million$41.50 millionViewListenView Earnings Details
11/9/2015Q3($0.21)($0.34)$40.84 million$53.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.04)$0.01$55.93 million$44.90 millionViewListenView Earnings Details
5/11/2015Q115($0.12)$0.25$32.90 million$33.80 millionViewListenView Earnings Details
3/2/2015Q414($0.16)$0.18$26.11 million$31.10 millionViewN/AView Earnings Details
11/13/2014Q314($0.16)($0.53)$19.40 million$21.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$9.39 million$11.80 millionViewN/AView Earnings Details
5/7/2014Q1$0.06$0.04$11.25 million$7.90 millionViewN/AView Earnings Details
3/31/2014Q413($0.14)($0.13)$8.38 million$7.10 millionViewN/AView Earnings Details
11/7/2013($0.03)$0.15$9.79 million$6.10 millionViewN/AView Earnings Details
9/19/2013Q2 2013$0.09($0.17)$22.00 million$6.78 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Intrexon (NYSE:XON) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Intrexon (NYSE XON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 56.30%
Institutional Ownership Percentage: 75.95%
Insider Trading History for Intrexon (NYSE:XON)
Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Intrexon (NYSE XON) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2018Randal J KirkCEOBuy1,000,000$12.50$12,500,000.00View SEC Filing  
11/13/2017Andrew J LastCOOBuy2,000$12.10$24,200.00View SEC Filing  
8/22/2017Robert B ShapiroDirectorBuy2,850$17.50$49,875.0043,157View SEC Filing  
8/14/2017Andrew J LastCOOBuy2,000$19.99$39,980.002,000View SEC Filing  
8/11/2017Dean J MitchellDirectorBuy5,000$18.33$91,650.0018,103View SEC Filing  
8/11/2017Donald P LehrInsiderBuy1,094$18.33$20,053.0228,249View SEC Filing  
8/11/2017Jeffrey Thomas PerezSVPBuy1,000$17.89$17,890.0012,537View SEC Filing  
8/11/2017Randal J KirkCEOBuy132,625$18.85$2,499,981.25View SEC Filing  
12/13/2016Randal J KirkCEOBuy34,606$28.90$1,000,113.40View SEC Filing  
12/12/2016Joel D LiffmanSVPBuy8,500$28.62$243,270.00158,500View SEC Filing  
12/1/2016Fred HassanDirectorBuy6,900$29.02$200,238.006,900View SEC Filing  
8/29/2016Nir NimrodiSVPBuy4,000$26.12$104,480.00View SEC Filing  
5/13/2016Randal J KirkCEOBuy41,830$23.92$1,000,573.60View SEC Filing  
12/11/2015Randal J KirkCEOBuy124,475$29.85$3,715,578.75View SEC Filing  
12/7/2015Randal J KirkCEOBuy237,525$30.69$7,289,642.25View SEC Filing  
12/4/2015Suma KrishnanSVPSell20,900$35.66$745,294.0042,000View SEC Filing  
1/27/2015Randal J KirkCEOBuy555,556$27.00$15,000,012.00View SEC Filing  
5/13/2014Donald LehrInsiderBuy1,850$15.99$29,581.5015,326View SEC Filing  
5/13/2014Randal KirkCEOBuy65,173$15.19$989,977.87View SEC Filing  
5/9/2014Kelly HuangSVPBuy3,200$15.78$50,496.003,200View SEC Filing  
5/9/2014Krish KrishnanCOOBuy20,900$14.21$296,989.0020,900View SEC Filing  
3/27/2014Randal KirkCEOBuy243,001$25.72$6,249,985.72View SEC Filing  
3/4/2014Gregory Ian FrostSVPBuy100,000$25.95$2,595,000.00100,000View SEC Filing  
8/13/2013Jeffrey B KindlerDirectorBuy33,000$16.00$528,000.00View SEC Filing  
8/13/2013Randal J KirkCEOBuy1,887,500$16.00$30,200,000.00View SEC Filing  
8/13/2013Thomas D ReedInsiderBuy1,800$16.00$28,800.00View SEC Filing  
8/13/2013Thomas R KasserSVPBuy5,000$16.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intrexon (NYSE XON) News Headlines

Source:
DateHeadline
Global Protein Engineering Market 2018-2022 - Key Vendors are Agilent Technologies, Genscript, Intrexon, Lonza ...Global Protein Engineering Market 2018-2022 - Key Vendors are Agilent Technologies, Genscript, Intrexon, Lonza ...
www.prnewswire.com - April 24 at 4:37 PM
Zacks: Brokerages Expect Intrexon (XON) Will Announce Quarterly Sales of $55.29 MillionZacks: Brokerages Expect Intrexon (XON) Will Announce Quarterly Sales of $55.29 Million
www.americanbankingnews.com - April 18 at 4:49 AM
Intrexon (XON) Subsidiary Exemplar Genetics Reports Rare Neurological Disease Model Cleared by FDA for ...Intrexon (XON) Subsidiary Exemplar Genetics Reports Rare Neurological Disease Model Cleared by FDA for ...
www.streetinsider.com - April 16 at 9:35 AM
Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research UseExemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use
finance.yahoo.com - April 16 at 9:35 AM
-$0.24 Earnings Per Share Expected for Intrexon (XON) This Quarter-$0.24 Earnings Per Share Expected for Intrexon (XON) This Quarter
www.americanbankingnews.com - April 16 at 1:19 AM
Is Intrexon Corporation (NYSE:XON) As Strong As Its Balance Sheet Indicates?Is Intrexon Corporation (NYSE:XON) As Strong As Its Balance Sheet Indicates?
finance.yahoo.com - April 13 at 4:43 PM
Technical Perspectives on Biotech Stocks -- Intrexon, Iovance Biotherapeutics, Jaguar Health, and Jazz PharmaTechnical Perspectives on Biotech Stocks -- Intrexon, Iovance Biotherapeutics, Jaguar Health, and Jazz Pharma
www.prnewswire.com - April 6 at 9:30 AM
Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.
finance.yahoo.com - April 6 at 9:30 AM
Analyzing Intrexon (XON) and National Research (NRCIB)Analyzing Intrexon (XON) and National Research (NRCIB)
www.americanbankingnews.com - April 4 at 7:14 PM
Intrexon (XON) Given Consensus Rating of "Hold" by AnalystsIntrexon (XON) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 3:38 PM
Why Is Intrexon (XON) Up 18.8% Since Its Last Earnings Report?Why Is Intrexon (XON) Up 18.8% Since Its Last Earnings Report?
finance.yahoo.com - April 2 at 10:00 AM
Zacks: Analysts Anticipate Intrexon (XON) Will Post Quarterly Sales of $55.29 MillionZacks: Analysts Anticipate Intrexon (XON) Will Post Quarterly Sales of $55.29 Million
www.americanbankingnews.com - April 1 at 5:02 AM
 Brokerages Expect Intrexon (XON) to Post -$0.24 EPS Brokerages Expect Intrexon (XON) to Post -$0.24 EPS
www.americanbankingnews.com - March 30 at 3:20 AM
Intrexon (XON) Subsidiary ActoBio Therapeutics Granted FDA Approval to Commence Phase Ib/IIa Trial with AG019 for ...Intrexon (XON) Subsidiary ActoBio Therapeutics Granted FDA Approval to Commence Phase Ib/IIa Trial with AG019 for ...
www.streetinsider.com - March 29 at 4:40 PM
Intrexon on go to start clinical study of novel approach to treat type 1 diabetesIntrexon on go to start clinical study of novel approach to treat type 1 diabetes
seekingalpha.com - March 29 at 4:40 PM
ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 DiabetesActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes
finance.yahoo.com - March 29 at 9:32 AM
Commit To Buy Intrexon Corp At $10, Earn 14.5% Using OptionsCommit To Buy Intrexon Corp At $10, Earn 14.5% Using Options
www.nasdaq.com - March 28 at 4:38 PM
 Analysts Expect Intrexon Corp (XON) Will Post Quarterly Sales of $55.29 Million Analysts Expect Intrexon Corp (XON) Will Post Quarterly Sales of $55.29 Million
www.americanbankingnews.com - March 15 at 2:13 PM
Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON - Business Wire (press release)Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON - Business Wire (press release)
www.businesswire.com - March 13 at 10:51 AM
Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XONNewman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON
finance.yahoo.com - March 13 at 10:51 AM
AquaBounty Technologies, Inc. Results for the year ended ... - GlobeNewswire (press release)AquaBounty Technologies, Inc. Results for the year ended ... - GlobeNewswire (press release)
globenewswire.com - March 10 at 4:49 PM
Intrexon Corp (XON) Given Average Rating of "Hold" by AnalystsIntrexon Corp (XON) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 10 at 3:38 PM
AquaBounty Technologies, Inc. Results for the year ended December 31, 2017AquaBounty Technologies, Inc. Results for the year ended December 31, 2017
finance.yahoo.com - March 8 at 4:46 PM
Fibrocell Science (FCSC) Announces FDA Allowance of IND for FCX-013 for Treatment of Moderate to Severe Localized SclerodermaFibrocell Science (FCSC) Announces FDA Allowance of IND for FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
www.streetinsider.com - March 7 at 9:48 AM
JPMorgan Chase & Co. Lowers Intrexon (XON) Price Target to $18.00JPMorgan Chase & Co. Lowers Intrexon (XON) Price Target to $18.00
www.americanbankingnews.com - March 5 at 3:03 PM
Intrexon (XON) Price Target Cut to $19.00 by Analysts at Bank of AmericaIntrexon (XON) Price Target Cut to $19.00 by Analysts at Bank of America
www.americanbankingnews.com - March 2 at 9:08 PM
Northland Securities Reiterates Buy Rating for Intrexon (XON)Northland Securities Reiterates Buy Rating for Intrexon (XON)
www.americanbankingnews.com - March 2 at 4:48 PM
Intrexon (XON) Announces  Earnings ResultsIntrexon (XON) Announces Earnings Results
www.americanbankingnews.com - March 1 at 9:12 PM
Intrexon Corporation to Host Earnings CallIntrexon Corporation to Host Earnings Call
finance.yahoo.com - March 1 at 4:51 PM
A Preview Of Intrexons Q4 EarningsA Preview Of Intrexon's Q4 Earnings
finance.yahoo.com - March 1 at 4:51 PM
Intrexon Announces Fourth Quarter and Full Year 2017 Financial ResultsIntrexon Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 4:51 PM
-$0.31 EPS Expected for Intrexon Corp (XON) This Quarter-$0.31 EPS Expected for Intrexon Corp (XON) This Quarter
www.americanbankingnews.com - February 24 at 1:20 AM
Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1stIntrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st
finance.yahoo.com - February 22 at 9:11 AM
Intrexon (XON) Scheduled to Post Earnings on TuesdayIntrexon (XON) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
B.C. creator of non-browning Arctic apple plans aggressive expansion after positive U.S. test runB.C. creator of non-browning Arctic apple plans 'aggressive expansion' after positive U.S. test run
www.msn.com - February 17 at 4:46 PM
Intrexon Corp (XON) Receives Average Recommendation of "Hold" from BrokeragesIntrexon Corp (XON) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 3:30 PM
$48.79 Million in Sales Expected for Intrexon Corp (XON) This Quarter$48.79 Million in Sales Expected for Intrexon Corp (XON) This Quarter
www.americanbankingnews.com - February 9 at 6:56 AM
Chesco gene therapy company seeks FDA OK to begin human testing of skin disorder treatment - Philadelphia Business JournalChesco gene therapy company seeks FDA OK to begin human testing of skin disorder treatment - Philadelphia Business Journal
www.bizjournals.com - February 8 at 6:28 AM
-$0.31 Earnings Per Share Expected for Intrexon Corp (XON) This Quarter-$0.31 Earnings Per Share Expected for Intrexon Corp (XON) This Quarter
www.americanbankingnews.com - February 7 at 1:10 AM
Intrexon (XON) Downgraded by ValuEngine to "Strong Sell"Intrexon (XON) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - February 4 at 6:52 AM
Better Buy: Intrexon Corporation vs. Celgene - Motley FoolBetter Buy: Intrexon Corporation vs. Celgene - Motley Fool
www.fool.com - January 28 at 3:27 PM
Better Buy: Intrexon Corporation vs. CelgeneBetter Buy: Intrexon Corporation vs. Celgene
finance.yahoo.com - January 28 at 3:27 PM
Intrexon (XON) Raised to Hold at Zacks Investment ResearchIntrexon (XON) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - January 22 at 1:36 PM
Intrexon Corp (XON) CEO Randal J. Kirk Buys 1,000,000 SharesIntrexon Corp (XON) CEO Randal J. Kirk Buys 1,000,000 Shares
www.americanbankingnews.com - January 22 at 9:32 AM
Intrexon Corp (XON) Expected to Post Earnings of -$0.31 Per ShareIntrexon Corp (XON) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - January 21 at 5:24 AM
Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters - PR Newswire (press release)Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters - PR Newswire (press release)
www.prnewswire.com - January 20 at 4:15 PM
Intrexon Corp (XON) Receives Average Recommendation of "Hold" from AnalystsIntrexon Corp (XON) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 5:50 PM
Why IBM, GNC Holdings, and Intrexon Slumped TodayWhy IBM, GNC Holdings, and Intrexon Slumped Today
finance.yahoo.com - January 19 at 4:41 PM
Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by UnderwritersIntrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
www.bizjournals.com - January 19 at 12:13 PM
BRIEF-Intrexon Prices Public Offering Of Common StockBRIEF-Intrexon Prices Public Offering Of Common Stock
www.reuters.com - January 17 at 10:33 AM

SEC Filings

Intrexon (NYSE:XON) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intrexon (NYSE:XON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intrexon (NYSE XON) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.